ABSI
Absci CorpNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$732.16M
P/E Ratio
—
EPS
$-0.84
Beta
2.01
52W High
$5.23
52W Low
$2.24
50-Day MA
$3.06
200-Day MA
$3.17
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Absci Corp
Absci Corp (ABSI) is an innovative biotechnology firm that leverages its advanced AI-driven biology platform to transform the drug discovery process. By enabling the rapid generation of high-quality proteins and therapeutic candidates, Absci minimizes development timelines and reduces costs, positioning itself as a leader in the biopharmaceutical sector. The company partners with various stakeholders to develop and manufacture next-generation therapies, emphasizing efficiency and precision. With a strong pipeline of collaborations and proprietary programs, Absci is set to make impactful contributions to modern medicine and the treatment of diseases.
Fundamentals
| Revenue (TTM) | $2.80M |
| Gross Profit (TTM) | $-77.92M |
| EBITDA | $-112.98M |
| Operating Margin | -5453.00% |
| Return on Equity | -62.50% |
| Return on Assets | -36.30% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $1.25 |
| Price-to-Book | 3.87 |
| Price-to-Sales (TTM) | 261.48 |
| EV/Revenue | 211.85 |
| EV/EBITDA | -0.39 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -2.30% |
| Shares Outstanding | $155.45M |
| Float | $143.28M |
| % Insiders | 13.06% |
| % Institutions | 75.01% |
Historical Volatility
HV 10-Day
127.92%
HV 20-Day
96.99%
HV 30-Day
90.96%
HV 60-Day
94.57%
HV Rank
67.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($8.03 target)
2
Strong Buy6
Buy1
HoldData last updated: 4/30/2026